PT - JOURNAL ARTICLE AU - Dedon, Liv R. AU - Yuan, Hanshu AU - Chi, Jinhua AU - Gu, Haiwei AU - Arias, Albert J. AU - Covault, Jonathan M. AU - Zhou, Yanjiao TI - Baseline gut microbiome and metabolites are correlated with alcohol consumption in a zonisamide clinical trial of heavy drinking alcoholic civilians AID - 10.1101/2024.04.02.24305199 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.02.24305199 4099 - http://medrxiv.org/content/early/2024/04/03/2024.04.02.24305199.short 4100 - http://medrxiv.org/content/early/2024/04/03/2024.04.02.24305199.full AB - Development and severity of alcohol use disorder (AUD) has been linked to variations in gut microbiota and their associated metabolites in both animal and human studies. However, the involvement of the gut microbiome in alcohol consumption of individuals with AUD undergoing treatment remains unclear. To address this, stool samples (n=48) were collected at screening (baseline) and trial completion from a single site of a multi-site double-blind, placebo-controlled trial of Zonisamide in individuals with AUD. Alcohol consumption, gamma-glutamyl transferase (GGT), and phosphatidylethanol (PEth)levels were measured both at baseline and endpoint of 16-week trial period. Fecal microbiome was analyzed via 16S rRNA sequencing and metabolome via untargeted LC-MS. Both sex (p = 0.003) and psychotropic medication usage (p = 0.025) are associated with baseline microbiome composition. The relative abundance of 12 genera at baseline was correlated with percent drinking reduction, baseline and endpoint alcohol consumption, and changes in GGT and PeTH over the course of treatment (p.adj < 0.05). Overall microbiome community structure at baseline differed between high and low responders (67-100% and 0-33% drinking reduction, respectively; p = 0.03). A positive relationship between baseline fecal GABA levels and percent drinking reduction (R=0.43, p < 0.05) was identified by microbiome function prediction and confirmed by ELISA and metabolomics. Predicted microbiome function and metabolomics analysis have found that tryptophan metabolic pathways are over-represented in low responders. These findings highlight importance of baseline microbiome and metabolites in alcohol consumption in AUD patients undergoing zonisamide treatment.Competing Interest StatementAJA is a consultant to Sobrera Pharmaceuticals. All other authors report no conflict of interest.Clinical TrialNCT02900352Funding StatementThis work was supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under grants AA027858, AA12722313, AA007290, and AA027055.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of VIRGINIA COMMONWEALTH UNIVERSITY and Yale University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw sequencing reads from the 16S amplicon sequencing are available via the National Center for Biotechnology Information (NCBI) Short Read Archive (SRA) under accession #PRJNA1065830.